Fig. 6

Clinical relevance of the Mettl3/CBX8/LGR5 axis in CC. a, The relative expression levels of CBX8 were assessed by qRT-PCR in 18 paired normal tissues and CC tissues. b, The protein expression of CBX8 was assessed by Western blotting in 6 paired normal tissues and CC tissues. c, The expression of CBX8 in normal tissues and CC tissues was assessed by IHC. d, The graph shows the results of Kaplan-Meier analysis of the disease-free survival (DFS) rate in CC patients in the TCGA database with high or low expression of CBX8. e, The graph shows the results of Kaplan-Meier analysis of the overall survival (OS) rate in CC patients with high or low expression of CBX8. f, The protein expression of CBX8 was assessed by Western blot in chemoresistant CC tissues (R1–6) and chemosensitive CC tissues (S1–6). g, Patients with chemoresistance had higher levels of CBX8, Mettl3, LGR5, CD133 and CD44 expression as assessed by IHC, while patients with chemosensitivity had relatively lower levels of CBX8, Mettl3, LGR5, CD133 and CD44 expression as assessed by IHC. h, The graph shows that CBX8 expression was positively correlated with LGR5, CD133, CD44 and EpCAM expression in an analysis of TCGA data. Data are shown as the mean ± SD of three replicates (*, P < 0.05; **, P < 0.01)